CD38 and Miyoshi myopathy: Although CD38 CAR-T cells targeting MM have been reported, there are still no approved CD38 CAR-T cell products for clinical use; thus, more novel CD38 CAR-T cell clinical treatments are needed to advance the treatment of hematological cancers.